New Alzheimer's drug

Concerns have been raised about Cassava Sciences' Alzheimer's drug candidate, simufilam, prompting the FDA to acknowledge ongoing scrutiny after the SEC charged the company with misleading claims. Meanwhile, the Alzheimer's Association recently celebrated 40 years of fundraising efforts, having raised over $87 million to support research into the disease, which affects over 6.7 million Americans. The approval of new drugs, such as Kisunla and lecanemab (Leqembi), has sparked hope, although recent investigations reveal troubling financial conflicts of interest among advisory panelists involved in FDA approvals. The European Medicines Agency has recommended rejecting lecanemab due to safety concerns, while the UK's health authority has deemed it too expensive relative to its benefits. As the landscape of Alzheimer's treatment evolves, patients and families remain cautious about new therapies amid ongoing debates about their efficacy and safety. The complexity of Alzheimer's disease continues to challenge researchers and regulatory bodies in their quest for effective solutions.